CheckMate914

Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta‐analysis - Mori - International Journal of Urology - Wiley Online Library

New Perioperative Strategies Emerge for High-Risk, Resectable RCC

ESMO22: CheckMate 914-studie naar adjuvant nivo+ipi bij RCC behaalt primaire uitkomstmaat niet - Oncologie

Adjuvant therapy options in renal cell carcinoma — targeting the metastatic cascade

ESMO 2022: Adjuvant Nivolumab Plus Ipilimumab vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy: Results From the Randomized, Phase 3 CheckMate 914 Trial

Toni Choueiri, MD on X: Masterful presentation by @motzermd reporting subgroup analyses from #CheckMate914 (part A). Exploratory analyses suggest tumor PD-L1 expression influenced outcome of adjuvant IPI+NIVO in pts with localized #RCC

Toni Choueiri, MD on X: Masterful presentation by @motzermd reporting subgroup analyses from #CheckMate914 (part A). Exploratory analyses suggest tumor PD-L1 expression influenced outcome of adjuvant IPI+NIVO in pts with localized #RCC

Strengthening Our Grip on Immuno-Oncology in Genitourinary Cancers: Understanding Science Through Stories

Fine-Tuning the Wave of Innovation in RCC

Adjuvant Therapy for Renal Cell Carcinoma: End Points, Outcomes, and Risk Assessments

ASCO GU 2022: Updates on Clinical Trials in Adjuvant Renal Cell Carcinoma

Frontiers Adjuvant therapy for renal cell carcinoma, finally a new standard?

옵디보, '신세포암'에서 희비 교차 < 암/혈액/희귀/소아청소년 < 암/혈액/희귀/소아청소년 < 학술 < 기사본문 - 메디칼업저버

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial - The Lancet

Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial